Suzhou Huiliao Biomedical has appointed Dr. Chen Zhong as the company's Vice President and Head of Nucleic Acid Drug Chemistry.

On April 29, 2022, Suzhou Huiliao Biomedical Technology Co., Ltd. announced the appointment of Dr. Chen Zhong as the company's Vice President, responsible for the research, development, and management of nucleic acid drug chemistry.

Dr. Chen Zhong, Vice President of Huiliao Biomedical:

Brief on Education and Professional Experience:

Graduated with a Ph.D. in Pharmacy from Soochow University in 2015.

Engaged in postdoctoral research in medicinal chemistry at the University of North Carolina at Chapel Hill, USA, from 2016 to 2017.

Served as a faculty member at Soochow University from 2009 to March 2022.

Dr. Chen Zhong boasts over two decades of experience in medicinal chemistry across academia and industry. He has managed and led the process development, preparation, and quality research of siRNA drugs, published more than 20 academic papers in international journals, and filed over 10 Chinese invention patents. In recent years, he has presided over and participated as a key member in several National Natural Science Foundation projects, major national science and technology projects for new drug creation, and national science and technology support programs.

During his tenure at Soochow University, Dr. Chen accumulated extensive project experience in the discovery and druggability research of small molecule chemical drugs, with projects he participated in successfully transferred to pharmaceutical companies and submitted for IND applications to the NMPA. In recent years, Dr. Chen has focused on nucleic acid monomer chemistry, nucleic acid delivery chemistry, the design, preparation, and quality research of small nucleic acid drugs, leading his team to complete the development of nucleic acid drug delivery technologies based on ligands (GalNac) or liposomes (LNP).

Dr. Zhong Tianyi, Founder and CEO of Suzhou Huiliao Biomedical Technology Co., Ltd., expressed, "We warmly welcome Dr. Chen Zhong to join Suzhou Huiliao Biomedical Technology Co., Ltd.! With his extensive research and industrial experience in nucleic acid drug chemistry, Dr. Chen's addition will significantly broaden our company's proprietary technology platform for nucleic acid drugs. We are very much looking forward to the rapid advancement of our nucleic acid product pipeline under Dr. Chen's leadership, aiding Suzhou Huiliao in moving towards the goal of becoming a globally competitive leader in RNA therapeutics."

Dr. Chen Zhong stated, "Nucleic acid drugs are set to become the third wave of modern pharmaceuticals, following small molecule drugs and protein antibodies. I am deeply honored to have the opportunity to join a pioneering biopharmaceutical company like Suzhou Huiliao, which is leading not just in China but internationally. I hope to leverage Suzhou Huiliao's exceptional technology platform and my accumulated experience in the field of medicinal chemistry to establish a rich nucleic acid chemical technology pathway for the company. Furthermore, I aim to strengthen collaborations with peers both domestically and internationally to expedite the development of affordable nucleic acid drugs for the Chinese populace."

#About Suzhou Huiliao #

Suzhou Huiliao Biomedical was established in Suzhou Industrial Park in May 2021 and has collaborated with Soochow University to co-found the "Soochow University - Huiliao Biomedical RNA Drug Collaborative Innovation Center" and the "Soochow University - Nucleic Acid Delivery Vector Collaborative Innovation Center."

The company's operations span various fields including mRNA drug research and development, production, clinical trial design, and data analysis, focusing on the development of mRNA technology-based infectious disease vaccines, cancer vaccines, cell therapy, and protein replacement therapies. Centered around the novel mRNA delivery formulation CLS system, the company is dedicated to developing an mRNA drug technology production platform with Chinese independent intellectual property rights. It has already assembled a founding team composed of seasoned industrial experts in the field of nucleic acid drugs, with over 60% holding master's or doctoral degrees.